Oral Presentations:
 
Primary results of PanCAN-SR1, a phase 1b study evaluating Gemcitabine, nab-Paclitaxel, Canakinumab, and Spartalizumabto target IL-1β and PD-1 in metastatic pancreatic cancer with correlative tissue and blood biomarker analysis by Paul Oberstein, MD
 
Single-cell sequencing elucidates the effects of chemotherapy on cancer cell heterogeneity and the tumor microenvironment of human pancreatic adenocarcinoma by Emily Kawaler, PhD and Daniel Weissinger, MD 
 
Poster Presentations:
 
Polymerase theta inhibition activates the cGAS-STING signaling pathway and elicits an immune response in homologous recombination-deficient pancreatic adenocarcinoma by Grace Oh, MD